Healey Don is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days.
Profile
Don Healey is the Chief Technology Officer of Adicet Bio, Inc., a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies for cancer and other diseases, including the ADI-001 program. The SEC filing context (CIK 0001643067) lists him as CTO in the most recent filing dated 2026-01-27, with no insider purchases or sales reported in that period. In his role, Healey leads the company’s technology strategy and development of gamma delta T cell platforms and product candidates such as ADI-001.
Role
Insider
Notability
52/100
Board memberships
Adicet Bio, Inc.
Awards & honors
Leads technology strategy for Adicet's gamma delta T cell therapy programs
Oversees development of ADI-001 and related gamma delta T cell platforms
Don Healey is the Chief Technology Officer of Adicet Bio, Inc., a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies for cancer and other diseases, including the ADI-001 program. The SEC filing context (CIK 0001643067) lists him as CTO in the most recent filing dated 2026-01-27, with no insider purchases or sales reported in that period. In …
Where can I see all of Healey Don's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
